[CAS NO. 59474-01-0] NSC 146109 hydrochloride

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [59474-01-0]

Catalog

HY-108638

Brand

MCE

CAS

59474-01-0

DESCRIPTION [59474-01-0]

Overview

MDL	-
Molecular Weight	316.85
Molecular Formula	C17H17ClN2S
SMILES	[H]Cl.NC(SCC1=C2C=CC=CC2=C(C)C3=CC=CC=C13)=N

For research use only. We do not sell to patients.

Summary

NSC 146109 hydrochloride is a small-molecule p53 activator that target MDMX and can be used for breast cancer research. NSC 146109 hydrochloride is a pseudourea derivative, promotes breast cancer cells to undergo apoptosis through activating p53 and inducing expression of proapoptotic genes ^[1] .

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility

In Vitro:

DMSO : 83.33 mg/mL ( 263.00 mM ; ultrasonic and warming and heat to 60°C)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.1561 mL	15.7803 mL	31.5607 mL
5 mM	0.6312 mL	3.1561 mL	6.3121 mL
10 mM	0.3156 mL	1.5780 mL	3.1561 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.5 mg/mL (7.89 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2.08 mg/mL (6.56 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.08 mg/mL (6.56 mM); Clear solution

* All of the co-solvents are available by MCE.

References

[1] Wang H, et al. A small-molecule p53 activator induces apoptosis through inhibiting MDMX expression in breast cancer cells. Neoplasia. 2011 Jul;13(7):611-9.